Login
Israel-Hamas Conflict
Memorial Day
Cannes Film Festival
Baseball
Social Media
World Cup
Premier League
Inauguration
Wrestling
Soccer
Champions League
Donald Trump
Sanctions
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Sylentis announces topline results of SYL1801 phase 2a study

Summary by modernretina.com
SYL1801 is a treatment for neovascular macular degeneration administered via eye drops.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
modernretina.commodernretina.com

Sylentis announces topline results of SYL1801 phase 2a study

SYL1801 is a treatment for neovascular macular degeneration administered via eye drops.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

modernretina.com broke the news in on Saturday, May 17, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal